Biolegend, 100743, Brilliant Violet 605™ anti-mouse CD8a Antibody, 125microl

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).
Application References(PubMed link indicates BioLegend citation): Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP) Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete) Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP) Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block) Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC) Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC) Shih FF, et al. 2006. J. Immunol. 176:3438. (FC) Kamimura D, et al. 2006. J. Immunol. 177:306. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete) Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed Lee CH, et al. 2009. Clin. Cancer Res. PubMed Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed Guo Y, et al. 2008. Blood 112:480. PubMed Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed Kenna TJ, et al. 2008. Blood 111:2091. PubMed Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed Medyouf H, et al. 2010. Blood 115:1175. PubMed Riedl P, et al. 2009. J. Immunol. 183:370. PubMed Apte SH, et al. 2010. J. Immunol. 185:998. PubMed Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed Cui L, et al. 2015. J Control Release. 206:220. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed Schmid MC, et al. 2018. Nat Commun. 9:5379. PubMed Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed van Os BW, et al. 2023. Front Cardiovasc Med. 10:1171764. PubMed Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed Kim E, et al. 2022. Immunity. 55:145. PubMed Ning J, et al. 2022. Cancer Immunol Immunother. 71:1863. PubMed Paik D, et al. 2022. Nature. 603:907. PubMed Merana GR, et al. 2022. Cell Rep. 39:110891. PubMed Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed Duong–Ly KC, et al. 2018. J Cell Sci. 131:17. PubMed Denk D, et al. 2022. Immunity. 55:2059. PubMed Tata A, et al. 2021. Oncoimmunology. 10:1933808. PubMed Nato G, et al. 2021. Sci Rep. 11:651. PubMed Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed Zhang S, et al. 2021. Cell. 184(8):2151-2166.e16. PubMed Yousif AS, et al. 2020. Immunity. 54(2):235-246.e5. PubMed Bilate AM, et al. 2020. Immunity. 53(5):1001-1014.e20. PubMed Leech JM, et al. 2020. Cell Host & Microbe. 26(6):795-809.e5.. PubMed Huai W, et al. 2019. J Exp Med. 216:772. PubMed Piper CJM, et al. 2020. Cell Reports. 29(7):1878-1892.e7.. PubMed Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed Lutes LK, et al. 2021. eLife. 10:00. PubMed Crncec I, et al. 2018. Mol Oncol. 12:514. PubMed Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed van der Veeken J et al. 2019. Immunity. 50(5):1202-1217 . PubMed Anderson CK et al. 2019. Cell Rep. 27(2):537-548 . PubMed Qiu F, et al. 2022. J Cancer. 13:2893. PubMed Teng ZX, et al. 2022. J Inflamm Res. 15:3187. PubMed Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed Chen L, et al. 2020. J Exp Med. 217:00:00. PubMed Samarchith P Kurup et al. 2019. Cell host & microbe. 25(4):565-577 . PubMed Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed Aldrich AL, et al. 2021. The Journal of Immunology. 206(4):751-765. PubMed Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed Toubal A, et al. 2020. Nat Commun. 3755:11. PubMed Chauveau A, et al. 2020. Immunity. 52:794. PubMed Li Q, et al. 2019. Front Pharmacol. 10:786. PubMed Wennerberg E, et al. 2022. Sci Transl Med. 14:eabe8195. PubMed , et al. 2021. Eur J Immunol. 51:2708. PubMed Chen X, et al. 2021. Cell Rep. 37:109991. PubMed Zhou AC, et al. 2019. J Immunol. 202:2482. PubMed Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed Shreeve N, et al. 2021. Immunity. 54(6):1231-1244.e4. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Tummers B, et al. 2020. Immunity. 52(6):994-1006.e8. PubMed Giampazolias E, et al. 2021. Cell. . PubMed Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed Olguín JE, et al. 2018. J Cancer. 9:239. PubMed Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed Robles-Oteiza C, et al. 2021. Dis Model Mech. 14:. PubMed Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed Murray MP, et al. 2022. Cell Rep. 38:110209. PubMed Shibuya M, et al. 2021. iScience. 24:103131. PubMed Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed Liu Y, et al. 2019. Sci Rep. 9:18970. PubMed Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed Du P, et al. 2022. Front Pharmacol. 13:805508. PubMed Scharschmidt TC, et al. 2017. Cell Host Microbe. 1.199305556. PubMed Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed Dupraz L, et al. 2021. Cell Reports. 36(1):109332. PubMed Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed Pritykin Y, et al. 2021. Molecular Cell. 81(11):2477-2493.e10. PubMed Chen J, et al. 2014. Cell Res. 24:1050. PubMed Mathur AN, et al. 2019. Immunity. 50:655. PubMed Imbratta C, et al. 2019. Sci Rep. 9:6135. PubMed Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed Young JS, et al. 2018. Front Immunol. 9:1385. PubMed Riopel M, et al. 2019. Mol Metab. 20:89. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID: AB_2561352 (BioLegend Cat. No. 100743) AB_2562609 (BioLegend Cat. No. 100744)
Structure: Ig superfamily, CD8α chain, 34 kD
Distribution: Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
Function: Co-receptor for TCR
Ligand/Receptor: MHC class I molecule
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Zamoyska R. 1994. Immunity 1:243. 3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.
Gene ID: 12525
UniProt: View information about CD8alpha on UniProt.org
Clone: 53-6.7
Regulatory Status: RUO
Other Names: T8, Lyt2, Ly-2
Isotype: Rat IgG2a, κ